Compare Charles Schwab Corporation Common Stock (SCHW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 9.9× Zimmer Biomet Holdings Inc's market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.32%). Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SCHW | ZBH | |
|---|---|---|
Market Cap | $167.52B | $16.95B |
Volume | 6,554,126 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $113.65 | $103.98 |
52-Week Low | $85.35 | $79.58 |
Typical Hold Time | 85 Days | 89 Days |
Enterprise Value | $153.97B | $24.02B |
Dividend Yield | 1.32% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.87, up 1.35% on the day, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.62 exceeding the $1.56 estimate. Revenue for 2025 reached $23.92 billion, driving a net income margin of 38.79%. Analyst consensus is bullish with a $120.33 price target, and recent news highlights growth in client assets and AI integration for advisors.
The outlook remains positive given strong profitability and market share gains, though technical weakness and interest rate sensitivity pose near-term risks. Earnings momentum and strategic initiatives like the Texas Stock Exchange listing support upside potential, but investors should monitor competitive pressures and macroeconomic volatility.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
